Sarepta Therapeutics said Thursday that it has temporarily stopped a clinical trial of its second-generation medicine for patients with a certain type of Duchenne muscular dystrophy due to a serious safety incident reported by a patient.
The Food and Drug Administration placed a clinical hold on the Sarepta drug, called SRP-5051, after a patient in the study experienced a “serious” decrease in blood-based magnesium, a condition known as hypomagnesemia.
SRP-5051 belongs to a new class of treatments, which Sarepta refers to as its “PPMO platform,” that has become more important for the company following significant setbacks with its efforts to develop a one-time gene therapy for Duchenne.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
